The tempering treatment with a medicines used to treat asthma reduce the need for urgent attention and hospitalization in people with COVID-19, señalaron investigators de la Oxford University.
The studio, supported by AstraZeneca, found that the budesonida inhalada administer patients with COVID-19 inside the siete días posteriores al inicio de los sintomas también redujo the time of recovery.
Budesonide is a corticosteroid that is used in the treatment of the large plaque of asthma and the pulmonary obstructive chronic disease (EPOC).
The results of the unlicensed study of phase 2, which was supported by the NIHR Oxford Biomedical Research Center (BRC), see publicaron en medRxiv.
Treatment
Los hallazgos de 146 people, from the wounds at the end of the day 800 micrograms of medicine during the day and at the other end of the day usual, suggests that budsonida inhalada reduce the risk of requiring urgent attention to hospitalization in a 90% during the 28 day study period.
Participants assigned to the Budesonida inhaler also carry one more rapid resolution of fever and less sinful persists after 28 days.
Professor Mona Bafadhel of the Nuffield Department of Medicine, University of Oxford, who directed the essay, signaled:
“He has produced important advances in hospitalized patients with COVID-19, but they are also important treat tempering illness to prevent clinical outbreaks and the need for urgent attention and hospitalization, especially for the miles of millions of people all over the world who have limited access to hospital care ”.
Bafadhel showed me most enthusiasm: “I believe that a drug is relatively safe, widely available and well studied, like an inhaled asteroid, can make an impact on the pressures that are experienced during the pandemic“.
The study also demonstrated that there was a reduction in persistent symptoms in women receiving budding.
The persistent symptoms after the initial COVID-19 illness turned into a major problem. Any intervention that can solve this problem will be a big step forward”
Aseveró Bafadhel
The assay is inspired by the fact that, in the first days of the pandemic, patients with chronic respiratory disease, and those who were inhaled with steroid steroids, were significantly inferred among those admitted to the hospital with COVID-19 .